Downregulation of critical oncogenes by the selective SK2 Inhibitor ABC294640 hinders prostate cancer progression

Molecular Cancer Research

Volumn 13, Issue 12, 2015, Pages 1591-1601

  Schrecengost, Randy S ^a   Keller, Staci N ^a   Schiewer, Matthew J ^b   Knudsen, Karen E ^b   Smith, Charles D ^a  

^a APOGEE BIOTECHNOLOGY CORPORATION   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 CHLOROPHENYL) N (4 PYRIDINYLMETHYL)ADAMANTANE 1 CARBOXAMIDE; ANDROGEN RECEPTOR; SPHINGOLIPID; 3-(4-CHLOROPHENYL)-ADAMANTANE-1-CARBOXYLIC ACID (PYRIDIN-4-YLMETHYL)AMIDE; ADAMANTANE; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; KCNN2 PROTEIN, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; PYRIDINE DERIVATIVE; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENETICS; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EARLY CANCER; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE ACTIVITY; GENE EXPRESSION; IC50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ADAMANTANE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; PYRIDINES; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84950336102     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0626     Document Type: Article

References (52)

1. Patel NK, Finianos A, Whitaker KD, Aragon-Ching JB. Advanced prostate cancer -patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag 2014;10:651-64.
2. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 2010;13:311-5.
3. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999; 91:1574-80.
4. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
5. Fromont G, Godet J, Peyret A, Irani J, Celhay O, Rozet F, et al. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. Hum Pathol 2013;44:1617-23.
6. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4: 223-38.
7. Fyrst H, Saba JD. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 2010;6:489-97.
8. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962-9.
9. Neubauer HA, Pitson SM. Roles, regulation, and inhibitors of sphingosine kinase 2. FEBS J 2013;280:5317-36.
10. Kunkel GT, Maceyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 2013;12:688-702.
11. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 2003;278:46832-9.
12. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 2000;275:19513-20.
13. Liu H, Toman RE, Goparaju SK, Maceyka M, Nava VE, Sankala H, et al. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem 2003;278:40330-6.
14. Gao P, Smith CD. Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration. Mol Cancer Res 2011;9:1509-19.
15. Weigert A, Schiffmann S, Sekar D, Ley S, Menrad H, Werno C, et al. Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int J Cancer 2009;125:2114-21.
16. Beljanski V, Knaak C, Zhuang Y, Smith CD. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs 2011;29: 1132-42.
17. Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010;151:5124-35.
18. Venkata JK, An N, Stuart R, Costa LJ, Cai H, Coker W, et al. Inhibition of sphingosine kinase 2 down-regulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood 2014;124: 1915-25.
19. Wallington-Beddoe CT, Powell JA, Tong D, Pitson SM, Bradstock KF, Bendall LJ. Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression. Cancer Res 2014;74:2803-15.
20. Gestaut MM, Antoon JW, Burow ME, Beckman BS. Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival. Pharmacol Rep 2014;66:174-8.
21. Maines LW, Fitzpatrick LR, French KJ, Zhuang Y, Xia Z, Keller SN, et al. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci 2008;53:997-1012.
22. Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ,Urban MW, Stanek TJ, et al. USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Res 2014;74:272-86.
23. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010;333:129-39.
24. Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 2010;333: 454-64.
25. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM.. MYC and Prostate Cancer. Genes Cancer 2010;1: 617-28.
26. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153: 141-8.
27. Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Semin Oncol 2013;40:244-58.
28. Tonelli F, Alossaimi M, Williamson L, Tate RJ, Watson DG, Chan E, et al. The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(pchlorophenyl) thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism. Br J Pharmacol 2013;168: 1497-505.
29. Schnute ME, McReynolds MD, Kasten T, Yates M, Jerome G, Rains JW, et al. Modulation of cellular S1P levels with a novel, potent, and specific inhibitor of sphingosine kinase-1. Biochem J 2012;444: 79-88.
30. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010. 21:315-24.
31. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. ARV7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38.
32. Ware KE,Garcia-Blanco MA, Armstrong AJ,Dehm SM. Biologic and clinical significance of androgen receptor variants in castration-resistant prostate cancer. Endocr Relat Cancer 2014;21:T87-103.
33. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-77.
34. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010;107:16759-65.
35. Mukhopadhyay A, Tabanor K, Chaguturu R, Aldrich JV. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment. Cancer Biol Ther 2013;14:962-72.
36. Lin CP, Liu JD, Chow JM, Liu CR, Liu HE. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 2007;18:161-70.
37. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003;22:6151-9.
38. Wang J, Ma X, Jones HM, Chan LL, Song F, Zhang W. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells. J Transl Med 2014. 12:226.
39. Kemppainen JA, Lane MV, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 1992; 267:968-74.
40. Qin Z, Dai L, Trillo-Tinoco J, Senkal C, Wang W, Reske T. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHVassociated primary effusion lymphoma. Mol Cancer Ther 2014;13: 154-64.
41. White MD, Chan L, Antoon JW, Beckman BS. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640. Anticancer Res 2013;33:3573-9.
42. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009;325:1254-7.
43. Vander Griend DJ, Litvinov IV, Isaacs JT. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. Int J Biol Sci 2014;10:627-42.
44. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 2003; 112:1724-31.
45. Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS ONE 2013;8:e63563.
46. Grad JM,Dai JL,Wu S, Burnstein KL. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated upregulation of AR messenger RNA. Mol Endocrinol 1999;13:1896-911.
47. Ni M, Chen Y, Fei T, Li D, Lim E, Liu XS, et al. Amplitude modulation of androgen signaling by c-MYC. Genes Dev 2013;27:734-48.
48. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014;510:278-82.
49. Choi PS, van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, et al. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci U S A 2011;108: 17432-7.
50. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001;7:235-9.
51. Leung JY, Andrechek ER, Cardiff RD, Nevins JR. Heterogeneity in MYCinduced mammary tumors contributes to escape from oncogene dependence. Oncogene 2012;31:2545-54.
52. Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and mitogen-Activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 2004;64:6190-9.